GH
Guardant Health, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$157.26
−2.35%Aug 25, 2026, 10:01 UTC
Callan Family Office LLC acquired a new stake in Guardant Health, Inc. by purchasing 6,080 shares valued at approximately $912,000 in the second quarter, as disclosed in its 13F filing.
Source:Aug 24, 2026, 21:53 UTC
On August 24, 2026, Guardant Health Inc's shares fell 4.4% to $163.18.
Source:Aug 24, 2026, 15:58 UTC
A Delaware federal judge finalized a ruling ordering Guardant Health to pay over $245.2 million to TwinStrand Biosciences and the University of Washington for willfully infringing two Duplex Sequencing patents, cementing a November 2023 jury verdict.
Source:Aug 14, 2026, 05:04 UTC
Guardant Health announced planned product launches in its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference.
Source:Aug 6, 2026, 21:38 UTC
Guardant Health Inc shares declined 3.4% on August 6, 2026, trading at $157.58.
Source:Aug 6, 2026, 01:36 UTC
Manulife Hong Kong and Macau partnered with Guardant Health to exclusively offer multiple cancer detection services to eligible customers in Hong Kong.
Source:Jul 31, 2026, 15:57 UTC
Zydus Lifesciences signed a Memorandum of Understanding with Apollo Hospitals to expand access to Guardant Health's Shield Multi-Cancer Detection test in India.
Source:Jul 31, 2026, 00:31 UTC
Guardant Health reported its Q2 2026 financial results, with a loss of $0.42 per share, missing the Zacks Consensus Estimate of a loss of $0.40 per share, compared to a loss of $0.44 per share a year ago.
Source:Jun 22, 2026, 11:53 UTC
The U.S. Food and Drug Administration approved Guardant360 Liquid CDx, a liquid biopsy panel developed by Guardant Health, Inc.
Source:Jun 11, 2026, 12:05 UTC
The FDA approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS.
Source: